Serum fibroblast growth factor 23 levels do not correlate with carotid intima-media thickness in patients with chronic kidney disease

Abstract EN

-High levels of fibroblast growth factor 23 (FGF 23) are associated with mortality and cardiovascular events in patients with chronic kidney disease (CKD).

Carotid intima-media thickness (CIMT) is a useful marker of subclinical atherosclerosis.

This study aimed to investigate the relationship between serum FGF23 levels and CIMT of CKD patients.

In this cross-sectional study, CIMT was measured in 162 patients with CKD Stage of 2–5 (age range 18– 79 years, 61.7% males).

Serum FGF23 levels were determined by enzyme-linked immunosorbent assay.

CIMT was measured by ultrasonography.

Serum FGF-23 levels were significantly higher (P = 0.046) in advanced CKD patients.

CIMT was thicker in patients with advanced CKD patients (P = 0.01).

CIMT was correlated with age (r = 0.486, P <0.001), smoking (r = 0.411, P <0.001), and 25-OH Vitamin D (r = −0.195, P = 0.045).

There was no correlation between serum FGF23 and CIMT.

Multivariate analysis showed that age (β = 0.373, P <0.001), smoking (β = 0.228, P = 0.004), and serum 25-hydroxyvitamin D levels (β = −0.164, P = 0.042) were associated with CIMT.

There was no relationship between FGF23 and CIMT.

The CIMT was found to be related to increased age, smoking, and 25-hydroxyvitamin D in CKD patients